Objectives: We aimed to assess the evidence for the use of 8-isoprostane in exhaled breath condensate (EBC) as a biomarker in adult asthma. Design: A systematic review and meta-analysis of EBC 8-isoprostane. Methods: We searched a number of online databases (including PubMed, Embase and Scopus) in January 2016. We included studies of adult non-smokers with EBC collection and asthma diagnosis conducted according to recognised guidelines. We aimed to pool data using random effects meta-analysis and assess heterogeneity using I 2 . Results: We included twenty studies, the findings from which were inconsistent. Seven studies (n = 329) reported 8-isoprostane levels in asthma to be significantly higher than that of control groups, whilst six studies (n = 403) did not.
Introduction
With the ascendance of personalised medicine and recognition of the heterogeneity within asthma there has been a drive to develop non-invasive measures of disease activity.
Collecting and analysing the condensate from exhaled breath (EBC) is one such method, studied since the early 1980's (1) . Several different commercial devices are available and this methodology has been adopted in a number of studies looking at an ever growing number of potential biomarkers.
Oxidative stress is thought to play an important role in asthma, as both a causative factor and a result of inflammation (2, 3) . It occurs where there is a failure of homeostasis -due either to an excess of reactive oxygen species (ROS) or to a lack of antioxidants -and can cause cellular damage, proinflammatory mediator release, mucous secretion, remodelling of extracellular matrix, smooth muscle contraction and bronchoconstriction (3) (4) (5) .
The reaction of ROS with other molecules is so rapid that their direct measurement is difficult; however, end products of ROS 'attack' are more stable and may be useful as surrogate markers for oxidative stress. 8-isoprostane is one such marker; specific to oxidative stress, stable, and measurable in EBC (6) (7) (8) . Paediatric studies of EBC 8- isoprostane have been the subject of a systematic review (9) which found the majority of studies reported a significant association between 8-isoprostane and asthma, however, as biomarker thresholds vary with age (10) , there is a need to review the adult literature.
We aimed to assess the evidence regarding the efficacy of EBC 8-isoprostane as a biomarker -its ability to identify disease, disease severity and response to treatment. We chose to conduct a comprehensive systematic review because this enables us to view the evidence as whole, and to identify common themes as well as inconsistencies that may only become apparent through evaluation of the entire dataset.
Methods

Study design
The study protocol was registered with and is available from the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD42016027312).
The primary objective of the review was to assess the ability of 8-isoprostane to identify and distinguish between a) those with asthma and healthy controls b) levels of asthma severity, and c) response to treatment. A secondary objective was to determine possible thresholds appropriate to a diagnosis of asthma or classification of severity.
Search Strategy
A search strategy was developed using terms relating to asthma, exhaled breath condensate and 8-isoprostane (see appendix table 1).
Two reviewers (AMP & CJCB) screened titles and abstracts for inclusion, resolving discrepancies through discussion with a third reviewer (YKL). The screening and selection process is described in a PRISMA flow chart (see figure 1) .
Fig. 1 -PRISMA Diagram
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Use of a custom EBC device with insufficient description or which fails to meet ATS/ERS guideline recommendations (11) .
Studies published as comment / letters will have a request for further information made; they will be excluded if further detail is not forthcoming.
Studies were excluded if the EBC collection device failed to meet ATS/ERS construction guidelines (12) (or was described insufficiently to determine this), or if the method of asthma diagnosis failed to meet recognised guidelines or was incompletely described. An exception to this was the use of nose-clips; although this was recommended, the guidelines state that there were no data underpinning this recommendation. A study by
Vass et al (13) published since the guidelines found no significant difference between samples collected with or without nose-clips (although 8-isoprostane was not one of the mediators studied).
During the initial screening process several conference abstracts were found. On contacting the authors it was confirmed that the results had not been published more fully elsewhere but insufficient information was forthcoming to determine suitability for inclusion. In order to avoid selective dissemination bias an analysis of these papers was included.
Data Extraction & Quality Assessment
Data extraction and quality assessment was conducted by two reviewers independently (AMP and CJCB). Data were extracted directly into SPSS (14); papers were assessed for quality and risk of bias (15) ; and the overall strength of evidence was assessed (16, 17) .
Discrepancies between the two reviewers were resolved through discussion with a third (YKL).
Statistical methods
We aimed to produce a quantitative synthesis using methods appropriate to the data extracted and to assess statistical heterogeneity using the I 2 statistic. We used Open-Meta
Analyst to conduct a random effects meta-analysis of mean difference (between asthma and control groups) for those studies reporting continuous data with a mean and standard deviation (SD). Where the SD was not reported we calculated it from confidence intervals or standard error (except where data had been transformed). In studies with multiple arms we combined data. We were not able to include papers which presented their results as a median and range.
Results
We identified 1,045 papers through the database search and a further five through reference searches (see PRISMA diagram, appendix figure 1 The time between reference and index standards was not clearly stated in five of the papers. The larger the interval the greater the risk of a change in condition between the two assessments and potential misclassification of asthma severity; we deemed asthma assessment within 1 week of EBC collection to be acceptable. Participant drop-out occurred in very few studies.
Variability: Pre-analytical
One study (Samitas et al (18)) coated the condenser surface of their EBC collection device in Tween-20 (a non-ionic surfactant) to reduce eicosanoid adherence. They report 8-isoprostane concentrations which are towards the higher end of results within this review.
The extent to which this was due to the use of Tween-20 is unclear; Sood et al (19) examined this method and found no significant difference in 8-isoprostane between samples collected with or without Tween.
Three studies (Battaglia et al (20) , Fritscher et al (21) and Sood et al (19) ) undertook or cited 8-isoprostane recovery rates obtained from spiking tests; all were over 90%. Sood et al found that concentrating their samples by lyophilisation had no effect on recovery rates, whereas Battaglia et al found lower rates when they used an immunoaffinity sorbent and lyophilisation.
Kostikas et al (22) cooled their condensing surface to minus 10 o C whereas other studies used minus 20 o C. We included this study as it does not contravene ATS/ERS recommendations and evidence on the effect of temperature on EBC 8-isoprostane collection is conflicting (23) (24) (25) .
Not mentioned in the ATS/ERS guidelines but specified by Cayman in their enzyme-linked immunosorbent assay (ELISA) information (26) is the use of an anti-oxidant -butylated hydroxytoluene (BHT) -for EBC samples which are being frozen and stored for later analysis. This is to prevent further (in vitro) oxidative formation of 8-isoprostane. The majority of studies using ELISA kits stored their samples for later analysis but none reported the use of BHT.
Relatively few studies reported the length of time samples were stored for but Samitas et al evaluated the stability of 8-isoprostane at minus 80 o C and found no significant difference in samples tested at one, four and eight weeks (although an upward trend could be noted).
Variability: Analytical
For their ELISA, Cayman cited a sensitivity of 3pg/ml and inter-assay variation rates of 10-24% however this validation was not undertaken in EBC. Sood et al (19) found the intra-assay CV in EBC to be 37.7% compared to 6% in buffer diluent. They concluded that interference from the EBC matrix was possible; the extent to which this might be a confounder in other studies is unclear as Sood et al's analysis was conducted on a lyophilised, concentrated EBC sample. The majority of studies in this review cite intraassay and inter-assay CV <10%.
Several studies utilised mass spectrometry techniques as their method of analysis -GCMS and LC-MS/MS methods offer improved sensitivity and selectivity over immunoassays, hence they are often regarded as the superior method for measurement of isoprostanes The absence of prime certified standard reference materials (SRM) produced by accredited bodies (such as NIST) for the production of calibration curves is a further source of potential inaccuracy and inter-laboratory variation.
Grade Assessment
A GRADE assessment was completed (using GradePro GDT (31)) for the twelve studies reporting on both asthma and control groups (see appendix table 4). The strength of the evidence pertaining to the differentiation of disease status was judged to be very low due to the inconsistency and imprecision of results.
Summary
For the majority of included papers there are no concerns over applicability to the review question but the risk of bias in the studies is largely unclear and there are unresolved methodological questions. Overall assessment of the evidence grade is very low.
QUANTITATIVE SYNTHESIS Prediction of asthma attack or treatment response
There were no studies examining the strength of association between 8-isoprostane concentration and frequency of asthma attack, nor studies examining the ability of 8-isoprostane to predict the risk of attack or response to treatment.
Differentiation of disease status
There was a large degree of clinical heterogeneity; studies examined different asthma phenotypes and severities, and utilised different interventions (including provocation tests and treatments). Given the broad study question we were addressing we considered the studies sufficiently homogenous for meta-analysis despite these differences.
Using Open Meta Analyst (32) we conducted a random effects meta-analysis of mean difference between groups (see figure 2 ). The estimated mean difference was +21.62 pg/ml in those with asthma (standard error 5.21). The p-value of <0.001 suggests statistical significance, and the lower bound of the meta-analytical point estimate -
11.4pg/ml -is above the detection limit for the ELISA (2.8 to 7pg/ml). However, the I 2 test result -94 -suggests a considerable degree of statistical heterogeneity, and the estimated mean difference (21.62pg/ml) should be viewed in light of the overall range of averages for EBC 8-isoprostane which varied from 0.25pg/ml to 78.10pg/ml.
Figure 2 -Random Effects Meta-Analysis of Mean Between-Group Difference (asthma vs controls)
Study weights: Kostikas 25%, Samitas 23%, Shimizu 25%, Zhao 27%.
________________________________________________________________________________________ QUALITATIVE SYNTHESIS
Ten papers (n = 419) reported average 8-isoprostane levels to be higher in asthma than in healthy controls, while five papers (n = 389) reported averages to be the same or higher in controls.
Of the ten studies reporting higher concentrations in asthma, only seven (n=329) reported the difference to be statistically significant. However, of the three which were excluded, two (22, 34) simply omitted to report the significance level, while the third study -Sood et al (19) -was not powered to detect a between-group difference in 8-isoprostane concentration.
With the exclusion of conference abstracts, five papers (n=248) report a significant difference, and five papers (n=278) report either no significant difference or higher concentrations amongst controls. All papers scored similarly in their quality assessment.
A full list of results can be found in appendix table 5.
Results from those papers reporting a median ( figure 3 ) and those reporting a mean (figure 4) are displayed below. Even when looking only at those studies reporting a significant between-groups difference, there is a considerable overlap of results between studies -the range of values for controls in one study being similar to those for asthma in
another. This degree of statistical heterogeneity precludes the determination of threshold values.
Figure 3 -Median 8-isoprostane and Range: Asthma groups versus controls Figure 4 -Mean 8-isoprostane and Standard Deviation: Asthma groups versus controls
There was a large degree of overlap in 8-isoprostane concentration between severities of asthma. This may be attributable to between-study methodological differences, however, three studies (18, 21, 35) made within-study comparisons of severity. Samitas et al (18) report a significant difference between the severe and milder asthma groups, whereas
Piotrowski et al (35) report a small, non-significant difference (0.87 pg/ml). Kostikas et al and concluded that condenser surface did have an effect but that there was no difference between polypropylene and teflon. Moreover they concluded that temperature difference between the two did not appear to have a significant effect on 8-isoprostane collection.
Based on current studies of methodology we cannot be certain that choice of device explains any of the heterogeneity in the results.
Regarding analytic method, if the outlier generated by the inclusion of conference abstracts (Sedlak et al (45)) is excluded, the results from mass spectrometry exhibit a smaller range and are considerably lower than the majority of results from ELISA. However, Carpagnano et al (34) -the only study to confirm their ELISA results using gas chromatograph-mass spectrometry -report no discrepancy between the two measures; this is in line with previous studies (46) . That analytical method is responsible for a degree of heterogeneity in the results is plausible but cannot be stated with certainty.
The inclusion of papers studying mild or intermittent asthma -in which there may be little or no oxidative stress -might explain the lack of consistently observed difference between asthma and control groups.
A sub-group analysis comparing moderate-to-severe asthma with controls was conducted to explore this possibility. Results were inconclusive; of the eight included papers (18, 22, 35, 45, (47) (48) (49) (50) five reported a between-groups difference (four of which were statistically significant) while three reported no difference (see appendix table 6).
Discussion
This review highlights a lack of comparability between studies, as well as evidence gaps which create difficulties in determining 8-isoprostane thresholds for diagnosis or severity classification of asthma. The clinical value of EBC 8-isoprostane as a quantitative assessment of oxidative stress in asthma remains unclear due to variability in results and inadequate standardization.
The previously published paediatric review (9) reported more consistent findings -five of the six identified studies found a significant difference between asthma and healthy control groups. However, the studies exhibited a similarly large degree of variance in their results (ranging between 4.2 -56.4pg/ml for asthma and 2.6 -34.2pg/ml for control groups).
The ATS / ERS taskforce of 2005 (11) was set-up to address variability in EBC results and lack of standardisation in methods. They suggested two likely contributors to variabilityvarying EBC dilution levels and biomarkers being at the lower end of assay sensitivity.
That there exists a large degree of variance in 8-isoprostane concentration levels even where studies have used the same EBC collection method would support these assertions.
Ahmadzai et al in 2013 (51) discuss three possible methods of calculating a dilution factor, none of which has established itself as a gold standard and none of which were used in the studies comprising this review. Only one study (30) used a dilution factor, giving their results in both pg/ml and parts per million of palmitic acid. It remains to be seen whether this improves reproducibility.
It has been suggested that lyophilisation may be useful for reducing variability by concentrating samples thereby raising biomarkers away from the lower end of assay sensitivity. There are a lack of studies examining the reliability and reproducibility of this method (51) . Unfortunately the only studies in this review to have used this approach (Battaglia et al (20) and Sood et al (19) ) concentrated their samples to differing levels (threefold and fourteenfold respectively). Furthermore, Sood et al reported an intra-assay CV of 37.7% and an inter-day CV of 71.6% when using this method.
The validity of any assessment of diagnostic test accuracy rests upon the accuracy of the reference standard to which it is compared; we included studies where diagnosis was conducted according to recognised guidelines.
A large number of exclusions were due to lack of diagnostic clarity; many undertook spirometry as a study measure rather than a diagnostic assessment and -unless reviewed by a physician and judged against a clearly described standard -can't be accepted as diagnostic confirmation. Furthermore, guidelines stress the importance of variable airflow obstruction to diagnosis; this cannot be assessed by a single spirometry measurement thereby complicating the process for any study wishing to have a rigorous diagnosis as the basis for inclusion.
Of concern were studies where it was neither explicitly stated that smokers were excluded, nor was smoking status featured in the participant description. There were six studies in which this occurred and over which there must be some concern that data might include that from smoking participants. This would be a potential confounder; there is evidence that EBC 8-isoprostane is significantly higher in smokers compared to healthy controls (52) and may increase in an acute smoking response (53) .
Another potential confounder is the effect of food and drink; sixteen of the studies did not mention fasting prior to tests. The ATS/ERS guidelines (12) state that eating and drinking do not affect the non-volatile components of EBC as far as is known, but Ahmadzai (51) point out that food & drink may elevate levels of oxidants in body fluids and has the potential to influence oxidant concentrations in EBC (although they identify no studies describing any such effect on 8-isoprostane). The extent to which this might constitute a confounder is unknown.
Several authors confirmed they were unable to measure 8-isoprostane in a majority of their samples (54) (55) (56) . Of those studies in this review which reported undetectable samples the percentage ranged from 16% (Komakula et al) to 50% (Piotrowski et al). Not all papers made clear the cause of missing data (whether an inability to obtain EBC samples or an inability to detect 8-isoprostane) nor how this was handled in the analysis. Gratziou et al (38) gave non-detectable levels of 8-isoprostane a value of 3.9pg/ml (the lower limit of assay detection) while Sood et al ascribed undetectable levels a value half the lower detection limit; neither state how many cases this applied to. If these samples came predominantly from healthy controls, raising them might obfuscate any difference between asthma and controls.
The absence of oxidative stress is a potential explanation of inability to detect 8-isoprostane. This might be the case for studies of mild or intermittent asthma. The use of provocation tests or the study of moderate-to-severe asthma is one potential approach to this problem but the results of such studies were no less conflicted.
Although not one of our primary objectives we examined those factors for which an association with 8-isoprostane was reported. The majority of studies which assessed GORD and BMI reported a significant association with 8-isoprostane. It is possible that these are important confounders which may need to be controlled for in future studies.
Limitations
By employing rigorous inclusion criteria for asthma diagnosis and EBC methodology several 'key' papers were excluded, including that of Montuschi et al (46) frequently cited by others as justification for their methodology. We believe these exclusions were justified; the use of rigorous inclusion criteria are crucial for a review of diagnostic test accuracy.
Inability to assess the risk of bias in key domains of the QUADAS-2 quality assessment tool makes any conclusions from this review necessarily tentative. Furthermore, we were able to conduct meta-analysis of only four studies due to the frequent use of median, range, and log-transformed data.
The increasing ability to examine several biomarkers -for example Sedlak et al (45, 47) -creates a risk that non-significant findings may go unreported unless high reporting standards are adhered to. Hussain et al mention EBC 8-isoprostane in the methods section of a conference abstract (57) but not in the results, nor anywhere in the full published paper (58); suggesting that 8-isoprostane was either undetectable or the results were non-significant. Although these may constitute a publication bias, the underrepresentation of negative findings makes the lack of positive findings in this review more robust.
Conclusion
There is a trend towards higher EBC 8-isoprostane concentrations in subjects with asthma compared to controls. Twice as many studies reported higher levels amongst those with asthma than did not. However the strength of this evidence is weak and the number of studies reporting a significant difference was the same as that reporting none. A random effects meta-analysis found a significant difference between groups however its rigour is compromised by the small number of studies and substantial statistical heterogeneity.
Concentrating EBC samples may address some of the variability and difficulty arising from the use of ELISA. However, the central issue of calculating EBC dilution cuts across analytical methods and a gold standard is still to be determined. It will be essential to develop accurate, reliable and standardised methods of both EBC collection and 8-isoprostane analysis if its use as a biomarker in asthma is to be properly evaluated.
Appendix Table 1 (Asthma* OR "Bronch* hyperreactivity") AND ("Exhaled breath condensate" OR "Breath test*" OR "Lung function test*" OR "Expired air") AND (*isoprostane* OR Dinoprost* OR *prost* OR "Lipid peroxid*" OR *prostaglandin*)
The strategy was modified as required for individual databases and the implemented in the following online databases: Cochrane, Embase, PubMed, Lilacs, Scopus, ClinicalTrials.gov, Open Grey and ProQuest. Reported difference between controls and asthmatics; Significance of difference.
. ..  = low risk / low level of concern regarding applicability ? = unclear risk / unclear level of concern regarding applicability  = high risk / high level of concern regarding applicability 
